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Abstract
Despite the wealth of knowledge regarding the mechanisms of action and the mechanisms of resistance to azole
antifungals, very little is known about how the azoles are imported into pathogenic fungal cells. Here the in-vitro
accumulation and import of Fluconazole (FLC) was examined in the pathogenic fungus, Candida albicans. In energized cells,
FLC accumulation correlates inversely with expression of ATP-dependent efflux pumps. In de-energized cells, all strains
accumulate FLC, suggesting that FLC import is not ATP-dependent. The kinetics of import in de-energized cells displays
saturation kinetics with a Km of 0.64 uM and Vmax of 0.0056 pmol/min/10
8 cells, demonstrating that FLC import proceeds via
facilitated diffusion through a transporter rather than passive diffusion. Other azoles inhibit FLC import on a mole/mole
basis, suggesting that all azoles utilize the same facilitated diffusion mechanism. An analysis of related compounds indicates
that competition for azole import depends on an aromatic ring and an imidazole or triazole ring together in one molecule.
Import of FLC by facilitated diffusion is observed in other fungi, including Cryptococcus neoformans, Saccharomyces
cerevisiae, and Candida krusei, indicating that the mechanism of transport is conserved among fungal species. FLC import
was shown to vary among Candida albicans resistant clinical isolates, suggesting that altered facilitated diffusion may be a
previously uncharacterized mechanism of resistance to azole drugs.
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Introduction
The incidence of invasive fungal disease has increased over 200%
in the US in the last 25 years [1], likely the result of a parallel
increase in the immunocompromised patient population. Candida
species are the most common invasive fungal pathogens, with
Candida albicans accounting for more than 50% of all infections [2].
C. albicans causes oral, vaginal and systemic disease, with the highest
morbidity rate (30%–50%) occurring with systemic Candida
infections in neutropenic transplant patients [3–5].
One of the first lines of defense for treating pathogenic fungal
infections are the azole drugs, including FLC, the most commonly
used azole. FLC and other azoles affect the biosynthesis of
ergosterol (the major sterol in the fungal plasma membrane) by
inhibiting 14a lanosterol demethylase, the product of the ERG11
gene. The significant increase in invasive fungal infections and the
prolonged and repeated treatment of AIDS patients has resulted in
a marked increase in the emergence of FLC-resistant C. albicans
isolates [6–8]. In C. albicans, several mechanisms of resistance have
been well characterized (reviewed in [6–8]). However, clinical
isolates have not been investigated for altered azole import as a
mechanism of resistance.
Several studies have investigated the accumulation of drugs in
resistant clinical isolates of C. albicans [7,9–12]. These studies show
reduced intracellular FLC in the isolates, which is energy
dependent and the result of overexpression of the major facilitator
pump gene MDR1, and the ABC transporter efflux pump genes
CDR1 and CDR2 [7,8]. Both Cdr1p and Cdr2p are ATP-
dependent efflux pumps, whereas Mdr1p utilizes proton motive
force at the membrane to transport drugs and other compounds.
Surprisingly, the mechanism(s) by which FLC enters the C.
albicans cell remain unstudied. Defects in drug import are a
common mechanism of drug resistance in other pathogenic
organisms, but to date, there have been no reports that C. albicans
utilizes altered import as a resistance mechanism. Azoles are
widely assumed to enter the fungal cell via passive diffusion [13–
15], but there is little evidence to support this. Some evidence for
facilitated diffusion of azoles has been reported, but these
experiments were performed in energized cells in which drug
efflux was active, and therefore failed to uncouple import and
export [9,16].
This study biochemically characterized the mechanism by
which FLC is taken into C. albicans cells. The results suggest that
the FLC enters the cell by energy-independent facilitated diffusion
in C. albicans and other pathogenic fungi. In addition, import levels
vary among resistant clinical isolates, suggesting that import is a
previously uncharacterized mechanism of resistance to azole drugs
in C. albicans.
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Fluconazole Uptake by C. albicans
The accumulation of [
3H]-FLC was analyzed in energized cells
in the presence of glucose (Fig. 1A), in which energy-driven
importers and efflux pumps would have an effect on drug
accumulation. Four C. albicans strains were tested: a wild type
strain (SC5314), a susceptible clinical isolate (#1), a matched
resistant clinical isolate that overexpresses CDR1, CDR2 and
MDR1 (#17, ref [17,18]) and a genetic construct strain DSY1050
that is deleted for CDR1, CDR2 and MDR1 [19]. Cells were
incubated with [
3H]-FLC and uptake was quenched by rapid
dilution and filtration as described in Experimental Procedures.
FLC accumulation was observed to be linear over 3 h, with
maximum accumulation observed after 24 h (Fig. 1), as accumu-
lation did not increase after 24 h (data not shown). In the presence
of glucose, the expression of efflux pumps does have a minor effect
on [
3H]-FLC accumulation: strain #17, which overexpresses
CDR1, CDR2 and MDR1, shows the lowest accumulation, and
strain DSY1040, which is deleted for the three pumps, shows the
highest level of accumulation.
Since FLC accumulation in the presence of glucose will be the
sum of both FLC import and export with ATP-dependent efflux
pumps, the strains were tested after glucose starvation for 2 h
(Fig. 1B). If import is energy-independent, the depletion of ATP
should inactivate ATP-dependent efflux pumps and accumulation
should largely be due to import. Under these conditions, there is
less variation between strains in the accumulation of [
3H]-FLC
and accumulation still occurred at a similar rate (Fig. 1B). The
addition of the glycolysis inhibitor 2-deoxy-D-glucose during the
2 h preincubation starvation did not alter [
3H]-FLC accumulation
levels, suggesting that the cells are indeed de-energized in the
absence of glucose (data not shown). This suggests that
accumulation does occur in de-energized cells and that efflux
pumps do not have an effect on FLC accumulation in the absence
of glucose.
Cells were inactivated to determine if import depends on living
cells. [
3H]-FLC did not accumulate when SC5314 cells were killed
by heat (70uC for 45 m; Fig. 1 and Table 1, row 1) or methanol
treatment (95% methanol for 45 m, Table 1, row 1). The heat-
killed and methanol-killed cells appeared intact when observed
under light microscopy. However, live cells were impermeable to
propidium iodide (,1.0% of cells were stained) while heat-killed or
methanol-killed cells were permeable to propidium iodide (98.8%
and 99.5% cells stained respectively), suggesting that the lack of
accumulation in killed cells is due to permeable cell walls and/or
membranes.
Effect of Condition Changes on [
3H]-FLC Import
Fig. 1 showed that all strains accumulate FLC in the absence of
glucose. A variety of conditions that might have an affect on azole
import were assayed for altered uptake of [
3H]-FLC (Table 1).
[
3H]-FLC accumulation is temperature dependent, with minimal
accumulation at 4uC and maximum accumulation at 30uC, with a
slight reduction at 37uC (Table 1, row 2). This is inconsistent with
passive diffusion of FLC, which should increase with an increase in
temperature. Import per cell was also studied during various
growth phases (Table 1, row 3) with maximum import occurring in
cells growing in mid-log phase (OD600 0.4). Germ tubes (hyphae)
exhibited a 4 fold increase in [
3H]-FLC accumulation when
compared to yeast cells (Table 1, row 4), although cell numbers are
difficult to determine for hyphal cells. Accumulation appears to be
unaffected by changes in pH (Table 1, row 5). Surprisingly, the
highest change in accumulation occurs under micro-aerophilic
conditions, where cells accumulate over 4 fold more than cells
growth with normal aeration (Table 1, row 6). The changes in
accumulation associated with growth and oxygen levels, and the
reduced import at higher temperatures confirms that accumula-
tion is not simply passive diffusion.
Kinetics of [
3H]-FLC Import
The high level accumulation of [
3H]-FLC in de-energized cells
(Fig. 1B) and the changes in accumulation with changes in the
environment (Table 1) suggest FLC import is carried out by
facilitated diffusion. Therefore, the kinetics of FLC import were
assayed in detail for de-energized SC5314 cells, studying the initial
rate of import across a spectrum of FLC concentrations (Fig. 2).
FLC import displayed saturation kinetics with a Km of 0.64 uM
and Vmax of 0.0056 pmol/min/10
8 cells. The saturation kinetics
strongly support facilitated diffusion through a specific transporter
as the mechanism of FLC import.
Competition of [
3H]-FLC Import by Other Azoles
To determine whether other azole drugs utilize the same
transporter as FLC, import of [
3H]-FLC was assayed in de-
energized SC5314 cells in the presence of unlabeled azole drugs
including FLC, ketoconazole (KTC), voriconazole (VRC), and
itraconazole (ITC). As seen in Fig. 3A, all four azoles inhibited the
import of [
3H]-FLC at 10 fold and 100 fold excess, suggesting that
the same transporter is involved in the uptake of all four azole
drugs.
50% inhibitory concentration (IC50) values were calculated for
KTC and ITC by measuring the rate of [
3H]-FLC import in the
presence of excess unlabeled KTC or ITC. The calculated IC50
values are 65 nM and 48 nM for KTC and ITC respectively
(Fig. 3B and data not shown). As 50 nM of [
3H]-FLC is used in the
assay, the IC50 values suggest that FLC, KTC and ITC compete at
equimolar concentrations for import into the cell, suggesting that
they compete equivalently as substrates for the transporter(s).
The antifungal 5-flucytosine (5FC) and the fluorescent dye
rhodamine 6G (R6G) have been hypothesized to share the same
import mechanism as FLC [10,20]. 5FC is a nucleoside analog
[20] and R6G is a dye known to be effluxed by Cdr1p and Cdr2p
[10]. However, neither 5FC (5 mM) nor R6G (5 mM) at 100 fold
Author Summary
Azole antifungals are used to treat a wide variety of fungal
infections of humans, animals and plants. A great deal is
known about how the azoles interact with their target
enzyme within fungal cells and how the azoles are
exported from the fungal cell through various efflux
pumps. Altered interactions with the target enzyme and
altered efflux pump expression are common mechanisms
of azole resistance in fungi. However, the mechanism by
which azoles enter a fungal cell is not clear—many have
assumed that azoles passively diffuse into the cell. This
study demonstrates that azoles are not passively diffused,
or actively pumped, into the cell. Instead, azoles are
imported by facilitated diffusion, mediated by a transport-
er. Facilitated diffusion of azoles is saturable. All clinically
important azoles, and many structurally related com-
pounds, compete for FLC import, while structurally
unrelated drugs do not compete. Azole import by
facilitated diffusion is shown in four species of fungi,
suggesting that it is common for most if not all fungi.
Altered facilitated diffusion is observed in a collection of
clinical isolates, suggesting that altered import is a
previously uncharacterized mechanism of resistance.
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3H]-FLC (Fig. 3A). These
observations suggest that 5FC and R6G have independent import
mechanisms, and that the assay does not measure drug export,
since R6G acts as a substrate for the efflux pumps.
Competition with Other Compounds
As FLC is unlikely to be the natural substrate for the import
mechanism, additional compounds were tested as competitors for
FLC import. The following types of compounds were tested in
molar excess and were shown not to compete with FLC: sugars,
nucleosides, amino acids, unrelated antifungals, salts and unrelated
drugs (complete list of compounds is in Table 2).
It is known that uptake of ergosterol increases under low-oxygen
conditions in Saccharomyces cerevisiae [21]. FLC import also increases
under low-oxygen conditions (Table 1, row 6). These observations
suggested that FLC and ergosterol might share an import
mechanism. However, 10 and 100 fold excess of unlabeled
ergosterol did not compete for [
3H]-FLC import in this assay (data
not shown).
In analyzing the competition data with FLC, ITC, KTC and
VRC (Fig. 3A), it became evident that all of the azoles share two
structural moieties in common – a) a halogenated aromatic 6
carbon ring and b) an imidazole [2 nitrogen (N)] or triazole (3 N)
5-member ring (Table 3, structures shown in Supplemental Figure
S1 based on the compound structures in the NIH PubChem
Compound Database [22]). Using this as a starting point, we have
expanded our understanding of the structural components that are
required to compete for FLC import (Table 3). Rows 1 to 8 show
the molecules that compete for FLC import, including the
clinically important FLC, VRC, ITC, KTC, and posaconazole,
as well as a fluorescein labeled ITC, and two agricultural azoles,
paclobutrazol and azaconazole. All of these compounds contain a
6-carbon ring halogenated with fluorine (F) or chlorine (Cl) and an
imidazole (2N) or triazole (3N) 5-member ring. Importantly,
fluorescein labeled ITC competes for FLC import, but it has no
antifungal activity on its own (data not shown). Many of these
compounds contain additional ring structures within the molecule
(Table 3 and Supplemental Figure S1).
Figure 1. Effect of glucose on [
3H]-FLC accumulation levels in C. albicans. A. FLC accumulation in the presence of 2% glucose. B. FLC
accumulation in the absence of glucose after cells were starved for 2 h. Strains = SC5314 (open squares), #1 (inverted triangles), #17 (triangles)
DSY1050 (open circles), heat-killed SC5314 (filled squares). Samples were removed at 1, 2, 3, and 24 h. Samples were normalized to CPM/1610
8 cells
(y axis) and compared to the incubation time (x axis). Error bars are included and most times are smaller than the symbol.
doi:10.1371/journal.ppat.1001126.g001
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sterol biosynthetic pathway and have antimicrobial activities,
including Tipifarnib, the Tipifarnib derivative 2g [23], STN54
[24], and Benznidazole. None of these molecules compete
(Table 3, rows 9–12). All four have a modified imidazole rings,
and two have aromatic rings without halogenation, suggesting that
one or both of these two structures are important for competition
of import.
To analyze these two components separately, the compounds
difluoro-benzene and imidazole were tested in the import assay
independently and together (Table 3 rows 13–15). The com-
pounds individually or in combination did not compete, suggesting
that a compound must have both moieties physically linked to
compete for FLC import.
Finally, the imidazole ring resembles histidine (H) and the
aromatic ring resembles phenylalanine (F). These two amino acids
alone do not compete for FLC import (Table 3, rows 16–17). To
test if physical linkage of H and F would compete for FLC import,
oligopeptides were prepared including the dipeptides HF and FH,
and larger peptides separated by one, two or three alanines (A)
(Table 2). None of these oligopeptides competed for FLC import.
To address concerns about peptide degradation, the peptides were
tested for competition of FLC import in the presence of protease
inhibitors, and at vast molar excess (10,000X) with no appreciable
competition.
Import of [
3H]-FLC in Other Pathogenic Fungi
FLC and other azoles are used in the treatment of many
pathogenic fungi. De-energized Cryptococcus neoformans, S. cerevisiae
and C. krusei, which is an intrinsically azole resistant Candida
species, were all tested for import of [
3H]-FLC and import levels
were compared to [
3H]-FLC import of C. albicans (SC5314). As
shown in Table 4, each species was able to import and accumulate
[
3H]-FLC at levels similar to C. albicans. Similar experiments with
equivalent OD units of E. coli cells did not detect FLC import
above background (data not shown), supporting the conclusion
that FLC import is not by passive diffusion. Collectively, these data
suggest that azoles are imported by a specific transporter that may
be conserved across fungal species.
Saccharomyces Gene Deletion Screen
S. cerevisiae shows FLC import similar to C. albicans (Table 4). To
ensure that known pumps are not involved in import, two S.
cerevisiae strains, AD1-8 and AD1-9 [25,26], which are deleted for
eight and nine efflux pumps respectively, were tested for import.
Import was not significantly different from the wild type strain
(data not shown).
Table 1. Effect of Condition Changes on [
3H]-FLC Import in SC5314.
Row Conditions Condition details Import
a Relative change
b
1 Killed Cells Methanol 289657 0.12
Heat 470645 0.20
2 Temperature 4uC 556654 0.24
25uC (WT) 23356193 1.00
30uC 28456130 1.22
37uC 25836417 1.11
3 Growth OD600 0.4 (log) 23,39461795 4.67
OD600 8–10 (post diauxic shift)(WT) 50076656 1.00
4 Morphology Germ tubes (Hyphae) 88266462 3.78
Yeast (WT) 23366193 1.00
5 pH pH 3 2754696 1.00
pH 5 (WT) 27666164 1.00
pH 7 25886187 0.94
pH 9 22996339 0.83
6 Low Oxygen Growth in micro-aerophilic conditions 119466466 4.55
Growth under normal conditions 26246174 1.00
aImport was analyzed as described in the Materials and Methods. Values are CPM/1610
8 cells 6 SE. Values are representative of three independent experiments.
Conditions were analyzed independent of other conditions.
bValues are relative to import of live SC5314 (WT) under standard conditions at 24 h.
doi:10.1371/journal.ppat.1001126.t001
Figure 2. Kinetics of import of [
3H]-FLC. Import kinetics measure
the initial accumulation rate (y axis) as a function of [
3H]-FLC
concentration (x axis), using C. albicans strain SC5314. The Michaelis-
Menten equation was used to determine Km of 0.64 uM and Vmax of
0.0056 pmol/min/1610
8 cells. Results are a representative graph of a
minimum of three independent experiments.
doi:10.1371/journal.ppat.1001126.g002
Azole Import into Fungi by Facilitated Diffusion
PLoS Pathogens | www.plospathogens.org 4 September 2010 | Volume 6 | Issue 9 | e1001126A collection of over 5,000 Saccharomyces strains containing
deletions in non-essential genes is available to the research
community [27]. The collection was screened biochemically, using
a 96 well format (see Materials and Methods). Two gene deletions
from the collection were identified that had significantly reduced
fluconazole import (Fig. 4). SNF7 and DOA4 are involved in protein
transport at the plasma membrane (reviewed in [28,29]). SNF7 is a
member of the ESCRT III complex (Endosomal Sorting Complex
Required for Transport) that is involved in recycling or degrading
membrane proteins. DOA4 is a de-ubiquitination enzyme involved
in the same process and physically interacts with SNF7. As these
proteins are both cytoplasmic and are involved in surface protein
processing, they are not likely to be directly involved in import, but
might be involved in subsequent processing of the import protein.
Other ESCRT proteins in the screen did not have a significant loss
of FLC import (data not shown).
One explanation for the role of SNF7 and DOA4 in FLC import
is that they may interfere with degradation of efflux pumps,
resulting in increased efflux. To test for efflux pump activity in snf7
and doa4 strains, R6G efflux was monitored over time (Fig. 5).
Mutant strains of snf7 and doa4 effluxed R6G at similar rates to the
wild type cells, while heat killed cells did not efflux R6G. The
similar rates of efflux for wild type and snf7 and doa4 mutants
indicate that reduced FLC import in these mutants (Fig. 4) is not
the result of increased efflux, even through the assay was
preformed with deenergized cells.
Figure 3. Imidazoles and triazoles compete for [
3H]-FLC uptake, but 5FC and R6G do not. Samples were grown and processed as outlined
in Experimental Procedures. (A) Influx was tested in the presence of 10 x (grey bars) and 100 x (black bars) molar excess of unlabeled azoles, 5FC or
R6G. Import of [
3H]-FLC was measured at 24 h post incubation. Values are the average of three biological replicates with standard deviations, shown
as a percentage of SC5314 import in the absence of unlabeled compounds. All azoles compete at a significant level at both 10X and 100X (p,0.05).
(B) To quantify competition for [
3H]-FLC import, increasing concentrations of unlabeled compound (KTC) were added to the incubation mixture and
samples were analyzed for [
3H]-FLC import at 10 m, 30 m, 60 m and 180 m. Using linear regression analyses, each square represents the rate of [
3H]-
FLC uptake in the presence of the unlabeled KTC. The kinetics are a measure of rate of import of [
3H]-FLC (y axis) as a function of the log of unlabeled
KTC concentration (x-axis). Dotted line graphically represents the calculation of IC50.
doi:10.1371/journal.ppat.1001126.g003
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FLC import when compared to wild type strains (data not shown).
This suggests that the role of SNF7 and DOA4 is not conserved
between the two species. It is not unusual for genes to have
different functions between the two species (i.e. [30–33]). It also
indicates that the role of SNF7 and DOA4 in S. cerevisiae is not
central to the mechanism of FLC import.
Import of [
3H]-FLC in Azole Resistant Clinical Isolates
To date, changes in azole import have not been reported as a
mechanism of antifungal resistance in C. albicans or other
pathogenic fungi. However, it is plausible that a mutation in the
azole transporter would lead to azole resistance. A collection of
unmatched clinical isolates of C. albicans was tested for their ability
to import [
3H]-FLC in the absence of glucose. Approximately
50% of the resistant isolates in this collection have unknown
mechanisms of resistance [34]. As seen in Fig. 6, of the 35 isolates
tested, four exhibited statistically significant alterations in [
3H]-
FLC import when compared to the median import value for all 35
isolates. Three of the isolates revealed significant decreases in
import, while one had a significant increase. In addition, there is
considerable variation in import between the other clinical isolates,
both above and below the mean. Of the isolates exhibiting
significantly decreased import, all exhibited other known but
Table 2. Compounds Unrelated to FLC That Do Not Compete for Inhibition of FLC Import.
Sugars Inositol, Mannose, Galactose, Glucose, Sucrose, beta 1–3 glucan (laminarin)
Nucleosides/Bases Adenosine, Thymidine, Guanosine, Cytosine, Uracil
Amino acids Cas-amino acids, Arg, Pro, His (H), Phe (F)
Oligopeptides HF, FH, HAF, FAH, HAAF, FAAH, HAAAF, FAAAH
Non-azole antifungals 5FC, Amphotericin B, Terbinafine, Fenpropimorph
Polyamines Spermidine, Spermine, Ornithine
Sterol Related Ergosterol, Farnesol, Dialkyl imidazole STN54
a
Salts CaCl2, CuSO4, FeSO4,K 2SO4, MgSO4, NaCl, and NH4SO4
Unrelated Drugs DNP (2,4-Dinitrophenol, oxidative phosphorylation inhibitor), CCCP (Carbonyl cyanide m-chlorophenyl hydrazone, oxidative
phosphorylation inhibitor), Brefeldin A (transport inhibitor), Rhodamine 6G (competes for efflux pumps)
All compounds were tested in the standard assay at 100x molar excess to [
3H] FLC and had no effect.
aSTN54 is a dialkylimidazole with very potent activity against C14-demethylease, the target of the azole drugs [24].
doi:10.1371/journal.ppat.1001126.t002
Table 3. Compounds Related to FLC and Assayed for Inhibition of FLC Import.
Row Compound Aromatic 6 carbon ring 5 member ring Additional rings Competition
a
1 FLC Halogenated (2 F) Triazole (2x) - +
2 VRC Halogenated (2 F) Triazole ++
3 ITC Halogenated (2 Cl) Triazole ++
4 Fluorescein-labeled ITC
b Halogenated (2 Cl) Triazole ++
5 Posaconazole Halogenated (2 F) Triazole ++
6 Paclobutrazol Halogenated (1 Cl) Triazole - +
7 KTC Halogenated (2 Cl) Imidazole ++
8 Azaconazole Halogenated (2 Cl) Imidazole ++
9 Tipifranib
c Halogenated (2 ring, 1 Cl each) Methylated Imidazole + -
10 Tipifarnib 2g
c Halogenated (2 ring - 1 Cl, and 1 Cl/
methylated)
Methylated Imidazole + -
11 STN54
d No halogenation (2 ring) Modified Imidazole + -
12 Benznidazole No halogenation Modified Imidazole - -
13 Difluoro-benzene Halogenated (2 F) No ring - -
14 Imidazole No ring Imidazole - -
15 Difluoro-benzene and Imidazole Halogenated (2 F) Imidazole -
16 His No ring Imidazole - -
17 Phe No halogenation No ring - -
aAll compounds were tested at 100x molar excess to FLC for their effect
bFluorescein-labeled itraconazole was prepared by J. Liu and collaborators (unpublished data), and has no anti-Candida activity (T. White and collaborators, unpublished
data).
cTipifarnib, an anti-cancer drug and the Tipifarnib analog JK11 (compound 2g) are both potent inhibitors of C14-demethylase, the target of the azole drugs [23].
dSTN54 is a dialkyl-imidazole with very potent activity against C14-demethylease, the target of the azole drugs [24].
doi:10.1371/journal.ppat.1001126.t003
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and overexpression of CDR1, CDR2 (both of which are inactive in
the import assay) or MDR1. The isolate with significantly increased
import had no known mechanism of resistance. It is possible that
these strains have altered import as well as other mechanisms of
azole resistance, as it is not uncommon for clinical isolates to have
multiple mechanisms of resistance [7,34].
Discussion
This study is the first to demonstrate and characterize facilitated
diffusion of FLC into C. albicans. This is achieved using
biochemical analyses. To date, FLC interactions with its target
enzyme and FLC efflux from the cell have been studied in detail,
but it was not known how FLC enters the fungal cell. With
increasing resistance to azole therapies, it is increasingly important
to understand mechanisms of FLC import and the contribution of
that import to clinical resistance.
Evidence of Facilitated Diffusion
The biochemical analyses clearly demonstrate that FLC import
into C. albicans is not the result of passive diffusion but the result of
facilitated diffusion. The biochemical evidence includes the
following:
a). Inactivated cells do not accumulate FLC, no matter the
method of inactivation: heat killing or methanol treatment
(Fig. 1 and Table 1). Passive diffusion should accumulate drug
whether the cell is living or dead.
b). The kinetics of FLC accumulation (Fig. 2) are not linear.
Linear accumulation with increasing drug concentration would
be expected for passive diffusion. However, the FLC accumu-
lation displays saturation kinetics with a Km of 0.64 uM (0.2 ug/
ml) and Vmax of 0.0056 pmol/min/1610
8 cells, strongly
indicating that FLC import proceeds via facilitated diffusion.
At low concentrations, the importer transports FLC into the cell
at an increasing rate as the FLC concentration increases, but at
higher FLC concentrations, the transporter becomes saturated
and the rate of import levels off. The Km of 0.2 ug/ml is below
the minimum inhibitory concentration (MIC) of the strain to
FLC (1 ug/ml).
c). The final intracellular concentration of [
3H]-FLC does not
exceed the extracellular concentration. This is consistent with
facilitated diffusion, and inconsistent with active transport,
which can accumulate drug to levels above the extracellular
concentration. Intracellular levels were estimated using the
results from this study (Fig. 1) and estimated cell volumes of
Saccharomyces cells [35]. The estimates suggest that the
intracellular concentration for [
3H]-FLC is 50 nM (data not
shown), which is the extracellular concentration that is used in
the assay.
d). Table 3 documents many compounds that will compete with
FLC for import, as well as many compounds that do not
compete. The ability for certain molecules to compete while
others can not compete is strong evidence that there is a specific
importer. Competition of specific compounds would not be
expected with passive diffusion.
Table 4. Import of [
3H]-FLC in Other Pathogenic Fungi




Cryptococcus neoformans 56046277 3.22*
Candida krusei 38026203 2.19*
Saccharomyces cerevisiae 22836322 1.31
Candida albicans 1737666 1.00
aImport was analyzed as described in the Materials and Methods. Values are
CPM/1610
8 cells 6 SE. Values are representative of three independent
experiments.
bValues are relative to import of Candida albicans under standard conditions at
24 h. *=p,0.05 relative to C. albicans.
doi:10.1371/journal.ppat.1001126.t004
Figure 4. [
3H]-FLC import in S. cerevisiae mutants. FLC import was
measured at 24 h for strains S288C (wild type), gene deletion snf7, gene
deletion doa4, and heat killed S288C. Import is expressed relative to
import in the wild type strain. Data is average of three biological
replicates. snf7, doa4, and heat killed cells are all significantly reduced
compared to wild type (p,0.05).
doi:10.1371/journal.ppat.1001126.g004
Figure 5. R6G Efflux of S. cerevisiae mutants. R6G efflux was
measured over time for strains S288C (wild type, squares), gene
deletion snf7 (triangles), gene deletion doa4 (inverted triangles), and
heat killed S288C (circles). At each time point, 10,000 cells were
measured for geometric mean fluorescence. Data is representative of
three independent experiments. Data is expressed as fluorescence
relative to the mean at t=0. The relative mean fluorescence (y axis) is
plotted against time in minutes (x axis).
doi:10.1371/journal.ppat.1001126.g005
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Surface
There is strong biochemical evidence that FLC is not simply
binding to the cells. First, the heat-killed and methanol-killed cells
do not show FLC accumulation (Fig. 1 and Table 1). If the drug
were binding to the cell wall, then the inactivated cells should also
bind to drug. In fact, these treatments might expose more cell wall,
resulting in more drug binding. However, FLC accumulation is
not observed in these cells. Second, the cell wall component beta
1,3 glucan, available commercially as laminarin, does not compete
for FLC binding (Table 2). It has been shown previously that cells
in biofilms bind to FLC and this binding can be competed with
laminarin [36]. However, laminarin had no effect on the FLC
import assay used in this study (Table 2), confirming that the
import assay and the biofilm assay are measuring separate
phenomena.
FLC Import Is Independent of Efflux Pumps
There is strong evidence that the results of these analyses are not
the result of the efflux pumps. In the assay, FLC import kinetics
were studied under de-energizing conditions (Fig. 2), in which the
efflux pumps are not active, and the results were not altered by the
addition of 2 deoxy-glucose (data not shown). In addition, the
pump mutant DSY1050 in which MDR1, CDR1 and CDR2 are all
deleted shows the same FLC import as wild type strains (Fig. 1).
Saccharomyces strains deleted for 8 to 9 efflux pumps that are known
to be associated with FLC efflux are still able to accumulate FLC
(data not shown). Finally, inhibitors of mitochondrial function,
including DNP and CCCP, that would eliminate function of
MDR1, as well as CDR1 and CDR2, had no effect on import
(Table 2).
General Azole Transporter
Azoles, including the clinically important FLC, KTC, ITC,
VRC and POS, as well as the agriculturally important
paclobutrazol and azaconazole, compete with labeled FLC for
import (Fig. 3A, Table 3). The imidazole KTC and the triazole
ITC compete at approximately equal molar concentrations
(Fig. 3B and data not shown). This supports the conclusion that
both imidazoles and triazoles utilize the same import mechanism
as FLC. Unrelated antifungals, including terbinafine, fenpropi-
morph and amphotericin B, do not compete and thus are unlikely
to use the same transporter.
Structural Analysis
By testing related drugs, the structural moieties within a
compound that allow it to compete with FLC for import were
defined (Table 3). Compounds that compete contain both a
halogenated (F or Cl) aromatic 6 member ring, and a triazole or
imidazole 5 member ring. Compounds that do not compete have a
methylation or other modification of the 5 member ring,
potentially coupled to non-halogenated aromatic rings.
The 5 member triazole or imidazole ring is necessary for
import, as compounds containing aromatic rings alone do not
complete:. Similarly, neither His nor imidazole compete, consis-
tent with the fact that neither contains an aromatic ring. The 6
member ring and the 5 member ring structures must be contained
on the same molecule, as a mixture of difluoro-benzene and
imidazole does not compete.
Given that His and Phe do not compete separately, it was of
interest to test the two amino acids together. Oligopeptides
containing His and Phe separated by 0 to 4 Ala did not compete
for FLC import (Table 2) suggesting that linked His and Phe,
which contain an imidazole ring and an aromatic ring, are not
sufficient for recognition of the FLC import mechanism.
5FC and R6G
Both 5FC and R6G have been suggested to be co-transported
with FLC. In a recent study, Noel et al. [20] characterized a series
of Candida lusitaniae isolates that were cross-resistant to 5FC and
FLC. The isolates tested were resistant to 5FC and susceptible to
FLC unless the compounds were used simultaneously, in which
case cross-resistance was observed. Noel et al. hypothesized that
5FC and FLC shared a common transporter and that extracellular
5FC was acting as a competitive inhibitor of FLC uptake transport
[20]. Later reports indicated that the cross resistance was in fact
due to mutations in genes encoding for cysteine permease [37] and
cytosine deaminase [38] indicating that cross resistance is not due
to a shared import mechanism. Data in this study support this
conclusion as 5FC does not compete for [
3H]-FLC import (Fig. 3).
R6G is a dye known to be effluxed from the cell by the pumps
Cdr1p and Cdr2p. R6G has been shown to be capable of
competing for FLC efflux [10]. It has therefore been hypothesized
that FLC is also imported by Cdr1p or Cdr2p acting in reverse
and that R6G could possibly compete for FLC import as well as
export [10]. Data from this study clearly indicate that R6G does
not compete for FLC import (Fig. 3).
A Common Azole Transporter Conserved across Varying
Fungal Species
Azoles are used to treat a wide variety of human (Candida,
Cryptococcus, Aspergillus) and agricultural (Pichia, Rhodoterula, Saccha-
romyces) fungal pathogens [39]. Based on this widespread use, it was
of interest to determine if other fungal species import and
accumulate [
3H]-FLC. It was shown that C. neoformans, S. cerevisiae
Figure 6. [
3H]-FLC import of FLC resistant clinical isolates. Each
circle represents the [
3H]-FLC import of individual clinical isolates
relative to the mean (y axis) at 24 h (x axis). Filled circles represent
isolates that vary significantly from the mean (long horizontal line) plus
standard deviations (shorter horizontal lines). Data is an average of four
independent experiments.
doi:10.1371/journal.ppat.1001126.g006
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3H]-FLC with similar kinetics (data not
shown) and to final levels similar to C. albicans (Table 4). In
addition the agricultural triazole paclobutrazol [40,41] and the
agricultural imidazole azaconazole [42,43] compete with FLC for
import (Table 3). These data suggest that the putative azole
transporter is conserved across various fungal species. Interesting-
ly, a recent study by Muller et al. [39] has shown that fungi found
in an agricultural environment (including, but not limited to,
various Candida, Cryptococcus and Saccharomyces species) are routinely
treated with fluquinconazole, penconazole, tebuconazole or
triadimenol. A significant portion of the isolates from different
species that are resistant to these agricultural azoles were cross
resistant to medical azoles including FLC, ITC, KTC or VRC.
The cross-resistance could be the result of over-expression of the
efflux pumps, but it is also possible that these isolates contain an
alteration in an azole importer that is conserved across various
fungal species and confers cross resistance to all azoles since all
clinically significant azoles compete for FLC import (Table 3 and
Fig. 3).
Characterization of the Saccharomyces Gene Deletion Set
for FLC Import
The biochemical screen for an importer in the haploid gene
deletion strain collection failed to identify a potential import
protein. The lack of a clear candidate suggests that the import
protein is either an essential gene, which can not be deleted and
would not be represented in the strain collection, or is present in
more than one version - two paralogs with the same function or a
gene family. In that case, deletion of one of the genes would not
eliminate FLC import. It is possible that with two paralogs, import
would be reduced 50% but that was not observed in the screen,
despite the use of two different time points. If the gene family
members or paralogs had substantially different kinetics, that
would have been detected in the kinetic analysis. However, if the
multiple copies of the importer all behave similarly, and the wild
type strain has all of the genes expressed, then the differences
would not be detected in the kinetic analysis. Further kinetic
analysis awaits the identification of the import protein.
The biochemical screen did identify SNF7 and DOA4, two
components of the ESCRT III complex involved in recycling and
degradation of surface proteins through the endosomes and multi-
vesicular bodies (MVB). SNF7 encodes one of the four subunits of
the ESCRT III complexes, and DOA4 encodes ubiquitin
isopeptidase that is closely associated with the complex. However,
the C. albicans snf7 and doa4 mutants did not exhibit a reduction in
import, suggesting that the role of SNF7 and DOA4 in S. cerevisiae is
not central to the import mechanism. The two gene deletion
strains, snf7 and doa4, do not have an altered MIC to FLC.
However, the efflux pump PDR5 is highly active in Saccharomyces
wild type strains, and may mask any effect of snf7 and doa4 on FLC
MIC. It is curious that other ESCRT proteins do not have an
altered FLC import. Further work awaits the identification of the
FLC import protein.
Modified Import as a Potential Resistance Mechanism
To date, there has been no report of altered FLC import as a
mechanism of antifungal resistance. The data in this study suggests
that all azoles utilize the same import mechanism mediated by a
transporter. Therefore, it is possible that a mutation in the putative
transporter would lead to azole cross-resistance. 35 unmatched
clinical isolates in which known mechanisms of resistance had
been documented [34] were evaluated for FLC import (Fig. 6).
Four of the 35 isolates exhibit significantly altered [
3H]-FLC
import. One of these four has no known mechanism(s) of
resistance, while the other three are known to overexpress
ERG11, MDR1, CDR1 and/or CDR2 or contain a mutation in
ERG11. However, it is common for clinical isolates to exhibit
multiple mechanisms of resistance [7,8,34]. Therefore, it is likely
that these isolates have mutations that affect [
3H]-FLC import, in
addition to other mechanisms of resistance. These data suggest
that loss, reduction, or alteration of azole import may be a
previously unknown mechanism of antifungal resistance.
In conclusion, this study uses biochemical analyses to demon-
strate that FLC import is not via passive diffusion but is in fact via
facilitated diffusion. The data presented here represents the first
comprehensive analysis of FLC import in C. albicans. This work
also demonstrates that azoles share a common transport
mechanism and azole import is conserved between several
pathogenic fungi. Future directions will be focused on identifying
and characterizing the protein responsible for this newly identified
FLC facilitated diffusion.
Materials and Methods
Organisms and Growth Conditions
Candida albicans SC5314 (from W. Fonzi; [44]) is the wild type
lab strain used in this study. C. albicans isolates #1 (2–76) and #17
(12–99) are a matched set of FLC susceptible and resistant clinical
isolates in which #17 overexpresses ERG11, CDR1, CDR2 and
MDR1. #1 and #17 are from a series of 17 oral isolates from a
single HIV positive patient [45]. C. albicans DSY1050 (from D.
Sanglard [19]) is a FLC hyper-susceptible strain containing
homozygous deletions of CDR1, CDR2 and MDR1. Cryptococcus
neoformans H99 (from J. Lodge; [46]), Candida krusei (our collection;
[47]) and Saccharomyces cerevisiae W303 (our collection; [48]) were all
used to determine if other fungal species are capable of importing
[
3H]-FLC. A collection of 35 un-matched clinical isolates (from D.
Stevens; [34] were used to determine import of [
3H]-FLC in
isolates with known and unknown mechanisms of resistance. The
Saccharomyces cerevisiae haploid gene-deletion library was originally
obtained from Research Genetics (Huntsville, AL).
Strains were maintained on YEPD (10 g of yeast extract, g of
peptone, 20 g of dextrose, with or without 15 g of Bacto Agar per
liter), or on CSM complete medium (0.75 g CSM [Bio 101; Vista,
CA], 1.7 g yeast nitrogen base without amino acids or ammonium
sulfate, 5 g ammonium sulfate, 20 g dextrose per liter). All isolates
were stored at 280uC in CSM or YEPD containing 10% glycerol.
Overnight cultures were inoculated from a single colony on a
YEPD agar plate and inoculated into YEPD broth and grown
overnight at 30uC, 180 rpm, unless otherwise noted.
Materials and Drugs
Medium components were obtained from Fischer Scientific
(Pittsburgh, PA) or Bio 101 (Vista, CA). General chemicals were
obtained from Fisher Scientific, or Sigma-Aldrich (St. Louis, MO).
Itraconazole, voriconazole, ketoconazole, paclobutrazol, azacona-
zole, flucytosine and R6G were obtained from Sigma-Aldrich (St.
Louis, MO). FLC was a generous donation from Pfizer, New York,
NY. Fluorescein-labeled ITC was the generous gift of J. Lui and
collaborators (Johns Hopkins U). POS, benznidazole, Tipifarnib,
Tipifarnib 2g, and STN54 were the generous gifts of Fred
Buckner, (U Washington). Oligopeptides were obtained from Neo
BioScience (www.neobiosci.com).
Fluconazole Uptake by Fungal Cells
FLC uptake was determined using [
3H]-FLC (specific activity
740 GBa/mmol, 20 Ci/mmol, 2610
4 CPM/pmol, 1 uCi/uL;
50 uM FLC; custom synthesis by Amersham Biosciences, UK).
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to a density typically between OD600 6.0 to 8.0, unless otherwise
noted. Cells were subsequently harvested by centrifugation
(30006g,5 m) andwashed three timeswith YNB complete (1.7 g
yeast nitrogen base without amino acids or ammonium sulfate,
5 g ammonium sulfate per liter, pH 5.0) without glucose (for
starvation) and without supplementation, unless otherwise
noted. Cells were resuspended at an OD600 of 75 in YNB for
2–3 h for glucose starvation. Reaction mixes consisted of 250 uL
of YNB, 200 uL of cells (75 OD) and 50 uL of [
3H]-FLC (1/100
dilution of stock). The resulting [
3H]-FLC concentration is
50 nM (0.015 ug/ml), which is significantly below the MIC for
all strains. Samples (100 ul) were removed at various time points
and placed into 5 ml stop solution (YNB +20 mM[ 6u g / m l ]
FLC), filtered on glass fibre filters (24 mm GF/C; Whatman;
Kent, UK) pre-wetted with stop solution and washed with 5 ml
of stop solution. Filters were transferred to 20 ml scintillation
vials. Scintillation cocktail (Ecoscint XR, National Diagnostics,
Atlanta GA) was added (15 ml) and the radioactivity associated
with the filter was measured with a liquid scintillation analyzer
(Tri-Carb 2800 TR; Perkin Elmer; Waltham, MA) and
normalized to CPM/1610
8 cells. Rate of [
3H]-FLC uptake
was determined by incubating samples in the presence of
increasing concentrations of unlabeled FLC (unless otherwise
noted) and samples were analyzed for [
3H]-FLC accumulation at
designated time points. These data were analyzed using linear
regression to determine the rate of [
3H]-FLC uptake. GraphPad
Prism 4.0 was used to determine linear regression, Michaelis-
Menten import kinetics (Vmax and Km) and 50% inhibitory
concentration (IC50)v a l u e s .
Uptake of [
3H]-FLC by a collection of 35 Candida clinical
isolates, and by the Saccharomyces gene deletion library was
determined by following the above protocol with the exception
that cells (1.5 ml) were grown for 48 h in 2.0 ml 96-deep well
plates (Masterblock; Greiner bio-one; Monroe, NC). The reactions
were half of the size: 125 uL of YNB, 100 uL of cells, and 25 uL of
[
3H]-FLC (1/100 dilution of stock). Samples (100 ul) from the
reaction were removed 24 h post incubation and filtered over 96-
well multiscreen HTS filter plates (Opaque non-sterile with lid,
1.2 mm glass fibre type C filter; Millipore, Billerica, MA), wells
were dried and the bottoms were sealed with sealing tape (Perkin
Elmer; Waltham, MA). Scintillation fluid (150 ul) was added to
each well, the tops were sealed with sealing tape and the plates
were counted on a 96-well liquid scintillation counter using both
top and bottom counting (Liquid Scintillation and Luminescence
Counter, WALLAC/Jet, 1450 Microbeta).
FACS Analysis of R6G Efflux
Isolates were grown to exponential phase in 5 ml YEPD at
30uC with 180 RPM shaking. Cells were collected by centrifu-
gation (30006g 5 m) and washed three times in sterile water.
Cells were resuspended to OD600=0.4 in 50 mM phosphate
buffer pH 6.0 with 5 mM 2-deoxy-D-glucose. Cells were
incubated for 60 m at 30uC with shaking. R6G was added to a
final concentration of 10 mm and cells were incubated for 90
minutes at 30u with shaking. Cells were collected by centrifuga-
tion and washed twice in 50 mM phosphate buffer pH 6.0. Cells
were resuspended to OD600=0.2 in 50 mM phosphate buffer
pH 6.0. 500 ml of cells was diluted 1:2 in 50 mM phosphate
buffer pH 6.0, and accumulation was measured by fluorescence
activated cell sorting (FACS). Glucose was added to a final
concentration of 40 mm and efflux was measured by analyzing an
aliquot of cells diluted 1:10 in ice-cold 50 mM phosphate buffer
pH 6.0 by FACS at the time intervals indicated using a Beckman
Coulter EpicsXL-MCL 4-colour cell analyzer. The geometric
mean of the fluorescence of each sample was calculated using
FlowJo software.
Characterization of FLC Import
Further studies were done to determine the effect of changes in
the incubation conditions have on FLC import:
Heat and methanol killed cells. Uptake of [
3H]-FLC was
determined in cells inactivated (killed) by heat (70uC for 45 m) and
methanol (95% methanol for 45 m). These conditions decrease
colony forming units greater than 100 fold compared to the
untreated culture. To assess permeability, cells were stained using
the Live/Dead FungaLight Yeast Viability Kit (Invitrogen), which
contains SYTO9 and propidium iodide. The stained cells were
analyzed by FACS (fluorescent activated cell sorting). After killing,
cells were harvested by centrifugation, washed with YNB complete
and resuspended at original density of OD600 75. Samples were
compared to live SC5314 cells.
Temperature. Cells grown overnight as previously discussed,
then incubated at 4uC, 25uC, 30uCo r3 7 uC for various times and
samples were removed and processed as described.
pH: Cells were incubated in YNB without supplementation
adjusted to pH 3, 5, 7 or 9 with potassium hydroxide (to increase
pH) or hydrochloric acid (to decrease pH) and processed at various
timepoints as outlined previously. Samples were compared to
pH 5 and recorded as relative change.
Growth phase. For each growth phase tested (log, late log,
post diauxic shift) cells were inoculated into YEPD broth at
varying concentrations and grown overnight. After overnight
growth, log phase cultures were harvested at OD600 0.4, late log
at OD600 2.0 and post diauxic shift at OD600 8–10. Samples
were harvested by centrifugation (30006g, 5 m) and processed
as previously described. All samples were compared to the post
diauxic shift sample and recorded as relative change. Post
diauxic shift samples were used for most of the analyses as it
reduces the sample volumes that must be processed for the
analyses.
Hyphal cells. SC5314 cells were grown overnight in YEPD
(30uC, 180 rpm). Cells were then washed three times with sterile,
distilled H20. Cells were diluted to a concentration three logs
below their overnight YEPD density in spider medium (10 g
nutrient broth, 10 g mannitol, 2 g dibasic K2HPO4 per liter) pre-
warmed to 37uC. Cells were then incubated at 37uC without
shaking until germ tubes formed (approximately 1 h). Hyphae
were washed two times with sterile, distilled H20 and resuspended
in YNB complete (no glucose) for 2 h until they were processed
and analyzed for uptake. Samples were compared to SC5314 yeast
cells.
Low oxygen. SC5314 cells were grown over night in YEPD.
In order to create a microaerophilic environment, a layer of
mineral oil was added to the surface of the sample and cultures
grown at 30uC without shaking, as previously described [49].
Samples were compared to SC5314 cultures at 30uC.
Supporting Information
Figure S1 Structures of compounds from Table 3. The
structures were drawn using freeware MarvinSketch v5.3.3. Most
of the structures were based on the compound structures in the
NIH PubChem Compound Database [49]. The structure of the
fluorescein labeled ITC in Table 3 is very similar to ITC, but the
exact structure has not been confirmed.
Found at: doi:10.1371/journal.ppat.1001126.s001 (0.22 MB
TIF)
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